EOC202 + albumin-bound paclitaxel

EOC202 + albumin-bound paclitaxel is an investigational **combination therapy** for cancer that includes EOC202 (mechanism and nature not specified in available public sources) administered together with **albumin-bound paclitaxel**, a microtubule inhibitor formulated to improve the delivery and safety of paclitaxel. Albumin-bound paclitaxel (nab-paclitaxel) uses albumin nanoparticles to transport paclitaxel, increasing tumor targeting and reducing solvent-related toxicity, and is indicated for a variety of cancers including breast cancer and pancreatic cancer. The combination is currently under clinical investigation for hormone receptor positive, HER2 negative advanced breast cancer[1].